A retrospective, multicenter, cohort study describing outcomes for Ibrutinib therapy in Relapsed/Refractory Marginal Zone Lymphoma
Latest Information Update: 11 Jan 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 11 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology